Go to the Globe and Mail homepage

Jump to main navigationJump to main content


Appetite for China IPOs still far from healthy Add to ...

Subscribers Only

Chinese IPO hopefuls are getting mixed messages. Fosun Pharmaceutical, whose name sounds the same as “revival” in Chinese, has raised $500-million (U.S.) in the first Hong Kong offering for three months. At the same time, however, a real estate trust backed by Li Ka-Shing has cancelled its Singapore listing. Despite a market recovery, the summer lull isn’t over yet.

Report Typo/Error

Next story




Most popular videos »

More from The Globe and Mail

Most popular